Senseonics (NYSEAMERICAN:SENS) posted its quarterly earnings data on Tuesday. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.11, Morningstar.com reports. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $7.89 million. Senseonics updated its FY 2019 guidance to EPS.
SENS stock opened at $3.03 on Wednesday. Senseonics has a 52 week low of $2.15 and a 52 week high of $5.29.
SENS has been the subject of a number of research reports. Piper Jaffray Companies initiated coverage on shares of Senseonics in a research report on Tuesday, January 29th. They set a “neutral” rating for the company. UBS Group initiated coverage on shares of Senseonics in a research report on Tuesday, November 27th. They set a “sell” rating for the company. Finally, Zacks Investment Research downgraded shares of Senseonics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 30th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $6.00.
COPYRIGHT VIOLATION NOTICE: “Senseonics (SENS) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.wkrb13.com/2019/03/13/senseonics-sens-posts-quarterly-earnings-results-beats-expectations-by-0-11-eps.html.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More: What is a Derivative?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.